Keyphrases
Antimicrobial Resistance
100%
Pseudomonas Aeruginosa (P. aeruginosa)
100%
Resistance-breaking
100%
Adjuvant Therapy
83%
Anti-resistance
83%
Cystic Fibrosis
50%
Lung
33%
Antibiotics
33%
Selective Pressure
33%
Antimicrobial Stewardship
33%
Adaptive Resistance
33%
Antimicrobial
16%
New Drugs
16%
World Health Organization
16%
Causative Agents
16%
Therapeutic Agents
16%
Intrinsic Resistance
16%
Genetic Disease
16%
Host Immune Response
16%
Cross-resistance
16%
Antimicrobial Therapeutics
16%
Emerging Infectious Diseases
16%
Bacterial Cells
16%
Antimicrobial Activity
16%
Shelf Life
16%
Global Conflict
16%
Acquired Resistance
16%
Resistance Mechanisms
16%
Antibiotic Treatment
16%
Resistance to Antibiotics
16%
Nosocomial Pathogens
16%
Immune Effectors
16%
Multidrug-resistant Pseudomonas Aeruginosa (MDRPA)
16%
Enhanced Penetration
16%
Resistant Strains
16%
Remaining Challenges
16%
Antibiotic Class
16%
Antibiotic Combination
16%
COVID-19 Pandemic
16%
SARS-CoV-2 Infection
16%
Secondary Bacterial Infection
16%
Multi-tiered
16%
Resistance to Antimicrobials
16%
Life Shortening
16%
High-stress Environments
16%
Acquired Resistance Mechanism
16%
Antibiotic Adjuvant
16%
Sanitizer
16%
Medicine and Dentistry
Antibiotic Resistance
100%
Pseudomonas aeruginosa
100%
Adjuvant Therapy
57%
Antiinfective Agent
42%
Cystic Fibrosis
42%
Pathogen
28%
Lung
28%
Antibiotics
28%
Lifespan
14%
Infection
14%
Therapeutic Agent
14%
Drive
14%
Antibiotic Therapy
14%
Genetic Disorder
14%
Bacterial Infection
14%
Adjuvant
14%
Cross Resistance
14%
Bacterial Cell
14%
Antimicrobial Activity
14%
Severe Acute Respiratory Syndrome
14%
COVID-19
14%
Emerging Infectious Disease
14%
Antimicrobial Therapeutics
14%
Antimicrobial Agent
14%
Pharmacology, Toxicology and Pharmaceutical Science
Pseudomonas aeruginosa
100%
Antimicrobial Resistance
100%
Antiinfective Agent
57%
Cystic Fibrosis
42%
Infectious Agent
28%
Antibiotics
28%
Genetic Disorder
14%
Infection
14%
Cross-Resistance
14%
Bacterial Infection
14%
Severe Acute Respiratory Syndrome
14%
Adjuvant
14%
Pandemic
14%
Antimicrobial Agent
14%
Diseases
14%
Immunology and Microbiology
Pseudomonas aeruginosa
100%
Antimicrobial Resistance
100%
Infectious Agent
28%
Lifespan
14%
Bacterial Cell
14%
Severe Acute Respiratory Syndrome
14%
Cross-Resistance
14%
Antimicrobial Activity
14%
Adjuvant
14%
COVID-19
14%
Antimicrobial Agent
14%